Treatment
Efgartigimod clinical trials
We’re tracking 27 recruiting studies that include Efgartigimod, each written for real people, not researchers, below.
Recruiting studies
- NCT05374590Enrolling by invitationPhase 2/Phase 3
Long-term safety study of efgartigimod for young myasthenia gravis patients
This trial checks the long-term safety of efgartigimod given through an IV and as a quick under-the-skin injection in children with generalized myasthenia gravis (gMG). It may help your care team understand how safely this treatment can be used over time for kids who already took related study treatments.
Chicago, IllinoisAges 2–18 - NCT07782775RecruitingPhase 1
Comparing two ways to give efgartigimod in healthy volunteers
This study compares two methods of giving the drug efgartigimod under the skin in healthy adults. It helps ensure both methods work the same way, which may make treatment easier for patients in the future.
MontrealAges 18–55 - NCT07284420RecruitingPhase 2
Testing empasiprubart with efgartigimod for myasthenia gravis
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
Carlsbad, CaliforniaAges 18 years+ - NCT06587867RecruitingPhase 3
Efgartigimod for seronegative myasthenia gravis
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
Toronto, OntarioAges 18 years+ - NCT07583641RecruitingPhase 2
Testing Efgartigimod for Autoimmune Brain Inflammation
This trial tests a medicine called efgartigimod to treat autoimmune encephalitis (AIE)—a rare condition where the immune system attacks the brain. The study enrolls children 12+ and adults to see if this drug can reduce symptoms and help recovery.
Tucson, ArizonaAges 12 years+ - NCT06655155RecruitingPhase 2
Testing efgartigimod for systemic sclerosis
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Phoenix, ArizonaAges 18 years+ - NCT07596849RecruitingPhase 3
Testing a New Injection for Graves' Disease
This study tests efgartigimod, a new medicine given by injection under the skin, to see if it can help control Graves' disease (an overactive thyroid condition). The goal is to reduce the need for other thyroid medications or help people stop taking them.
SurreyAges 18 years+ - NCT07294170Recruiting
Testing Multiple Treatments for Myasthenia Gravis
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
Carlsbad, CaliforniaAges 18 years+ - NCT07570316RecruitingPhase 3
Testing efgartigimod for Graves' disease hyperthyroidism
This study tests whether efgartigimod, an injectable medication given under the skin, can help control overactive thyroid (Graves' disease) in adults already taking methimazole or carbimazole. The goal is to see if it reduces thyroid antibodies and improves thyroid hormone levels.
Orange, CaliforniaAges 18 years+ - NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT06831058RecruitingPhase 2
Efgartigimod for preventing iTTP relapses
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Minneapolis, MinnesotaAges 18 years+ - NCT06860633RecruitingPhase 4
Efgartigimod for worsening myasthenia gravis in hospital
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
Aurora, ColoradoAges 18 years+ - NCT06909214RecruitingPhase 4
Study of efgartigimod for new-onset generalized myasthenia gravis
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
La Jolla, CaliforniaAges 18 years+ - NCT07217587RecruitingPhase 3
Comparing two drugs for generalized myasthenia gravis
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Fullerton, CaliforniaAges 18–74 - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Phoenix, ArizonaAges 18 years+ - NCT04833894RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This trial studies how efgartigimod (given through a vein) behaves in children and whether it is safe and effective for generalized myasthenia gravis. It is designed for children who have not done well enough with standard treatments like steroids or other immune medicines.
Chicago, IllinoisAges 2–18 - NCT06298565Recruiting
Safety study of efgartigimod for generalized myasthenia gravis
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
San Francisco, CaliforniaAges 18 years+ - NCT06299748Recruiting
Efgartigimod safety study for pregnancy and breastfeeding
This study is for women who have taken efgartigimod (a medicine for certain autoimmune conditions) right before or during pregnancy, or while breastfeeding. Researchers will monitor moms, fetuses, and babies to check for side effects and ensure safety.
Morgantown, West VirginiaAges Any age - NCT06392386RecruitingPhase 2/Phase 3
Efgartigimod for children with generalized myasthenia gravis
This study tests an investigational drug called efgartigimod for children and teens with generalized myasthenia gravis. It may help those who haven't responded well enough to standard treatments.
Charlotte, North CarolinaAges 2–17 - NCT06453694RecruitingPhase 2
Efgartigimod for first-time optic neuritis
This trial tests a drug called efgartigimod for people having their first episode of optic neuritis (inflammation of the optic nerve). The goal is to see if it can help protect your vision better than standard treatment alone.
Boston, MassachusettsAges 18 years+ - NCT06544499RecruitingPhase 3
Efgartigimod for adults with chronic ITP
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
Phoenix, ArizonaAges 18 years+ - NCT06765161RecruitingPhase 3
Efgartigimod for IVIG-dependent myasthenia gravis
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
Gatineau, QuebecAges 18–80 - NCT07072988RecruitingPhase 4
Steroid reduction with efgartigimod in older adults with generalized myasthenia gravis
This trial tests if a new drug called efgartigimod can help older adults with generalized myasthenia gravis safely reduce their steroid dose. The goal is to manage the disease with fewer steroid side effects.
Nice, Alpes-MaritimesAges 65 years+ - NCT07264426Recruiting
Real-world study of efgartigimod for CIDP
This study looks at how well efgartigimod works in everyday use for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to understand the real-world benefits of this treatment.
Wilmington, North CarolinaAges 18 years+
What Efgartigimod is being studied for
Conditions with recruiting Efgartigimod studies.
Common questions
- Are there clinical trials studying Efgartigimod?
- Yes. Clin2 currently lists 27 recruiting studies that include Efgartigimod, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Efgartigimod trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Efgartigimod an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Efgartigimod or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.